30 SKIN CARE A
10 8 6 4 2 0
Placebo ■ 2% Zenerity biotech ingredient ■
7.6% ****
4.8% ****
B 0 days 28 days
7 days
28 days
Female volunteer 24, 51 years old
Figure 8: A) Variation (%) in the ITA° parameter on the cheek vs. initial time: ****p<0.0001; vs. placebo: **p<0.01 (7 days), ****p<0.0001 (28 days). B) Representative images of improvement in dark spots pigmentation
Immediate redness reduction Skin redness, a key characteristic of sensitive skin, was evaluated before and after 30 minutes application of the cream using LifeViz Infinity (Quantificare) for lateral face macrophotographs. A specific filter quantified redness within a predefined mask, which was then superimposed on the digital images. The active cream showed a statistically significant reduction in skin redness in the delimitated facial region (Figure 9A, 9B) demonstrating an immediate effect on sensitive skin.
Decreasing skin roughness The skin roughness parameter (Sa) of the cheek was assessed by means of a real 3D microtopography imaging system based on fringe projection (PRIMOS). As shown in Figure 10A, a decrease in the
roughness parameter was obtained, with a greater decrease in the unhealthy group. An improvement of the skin roughness in the cheek
A
0 -1 -2 -3 -4
B Initial time
area can be appreciated (Figure 10B), indicating that skin is smoother in appearance therefore improving the sensitive skin condition.
Minimizing the appearance of wrinkles The wrinkle length parameter (µm) was evaluated on the crow’s feet and forehead areas by means of PRIMOS. The active cream showed a reduction of the length of wrinkles in a statistically significant manner in both regions (Figures 11A, B). Moreover, a visual reduction in the appearance of wrinkles can be observed from the facial images (Figures 11C, D).
Decreasing the appearance of dark spots The number of dark spots was evaluated from lateral macrophotographs of the face taken with the FrameScan software (Orion Concept) through image analysis applying a specific colour filter from cross-polarized images. The results showed a statistically significant
decrease in the number of dark spots, showing greater reduction in the unhealthy group
Placebo ■ 2% Zenerity biotech ingredient ■ A -2.8% After 30 min B
0 -1 -2 -3 -4 -5 -6
0 days
(Figure 12A). In the images (Figure 12B), a decreased appearance of dark spots over time can be appreciated, achieving a more homogeneous skin tone.
Conclusion The Zenerity biotech ingredient emerges as an innovative and comprehensive solution for sensitive skin, with anti-ageing benefits, by mimicking the advantages of a healthy anti- inflammatory diet within the skin. This novel active ingredient, a biotechnological extract isolated from thermal springs in Italy and enriched with nourishing minerals, effectively reduces skin inflammation, even in cases where an unhealthy diet exacerbates the condition. Moreover, it maintains optimal skin health,
alleviates the physical signs of skin sensitivity, and rejuvenates the skin to achieve a youthful appearance. By incorporating the biotech ingredient into
sensitive skin cosmetic formulations, brands and manufacturers can provide consumers
Placebo ■ 2% Zenerity biotech ingredient ■
-4.6% 28 days
Female volunteer 6, 40 years old
Figure 9: A) Variation (%) in the skin redness after 30 minutes of product application (****p<0.0001 vs. initial time). B) Representative images showing a reduction in skin redness after only 30 minutes of a single application of the active cream
PERSONAL CARE June 2024 Female volunteer 74, 48 years old
Figure 10: A) Variation (%) in the skin roughness parameter. B) Representative PRIMOS images showing an improvement in skin smoothness
www.personalcaremagazine.com
Redness mean variation (%)
ITA° mean variation (%)
Cheek roughness mean variation (%)
Height (um) -150 -100 -50 0 50 100 150 200
****
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68 |
Page 69 |
Page 70 |
Page 71 |
Page 72 |
Page 73 |
Page 74 |
Page 75 |
Page 76 |
Page 77 |
Page 78 |
Page 79 |
Page 80
